The high activity values of compound 14 against both wild-type and mutant c-KIT/PDGFRα showed the potential of the pyrazolopyridine derivatives as c-KIT/PDGFRα inhibitors for the treatment of imatinib-resistant GIST. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.